Welcome to our dedicated page for Immunic news (Ticker: $IMUX), a resource for investors and traders seeking the latest updates and insights on Immunic stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Immunic's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Immunic's position in the market.
Rhea-AI Summary
Immunic, Inc. (IMUX) to Release Q4 and Year-End 2023 Financial Results on February 22, 2024, with a Corporate Update. Webcast Scheduled at 8:00 am ET.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.29%
Tags
-
Rhea-AI Summary
Immunic, Inc. (IMUX) is set to participate in BioCapital Europe 2024 and ACTRIMS Forum 2024, where they will present poster presentations on the impact of Vidofludimus Calcium on Serum Neurofilament in Progressive MS and its potential to reduce fatigue in Multiple Sclerosis by blocking EBV reactivation.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.36%
Tags
-
Rhea-AI Summary
Immunic, Inc. (Nasdaq: IMUX) reported positive interim data from the phase 2 CALLIPER trial of vidofludimus calcium in PMS, improvements in gut health demonstrated in phase 1b clinical trial of IMU-856 in celiac disease, and expanded vidofludimus calcium patent portfolio. The company also announced a strengthened balance sheet and a three-tranche private placement of up to $240 million, extending its cash runway into the third quarter of 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.8%
Tags
Rhea-AI Summary
Immunic, Inc. (IMUX) enters into a securities purchase agreement with accredited investors for a three-tranche offering, expecting to raise between $160 and $240 million. The company plans to use the net proceeds to fund the ongoing clinical development of its lead product candidates and for general corporate purposes, with an expected funding into the third quarter of 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.8%
Tags
-
Rhea-AI Summary
Immunic, Inc. (IMUX) has received a Notice of Allowance for a new patent covering the treatment of multiple sclerosis (MS) with vidofludimus calcium, extending protection into 2038 in the U.S. and internationally. The patent also includes specific dose strengths for relapsing MS treatment, adding to the company's multilayered intellectual property strategy. Vidofludimus calcium is covered by several layers of granted patents in the U.S., Europe, and other jurisdictions, providing protection into 2041, with pending applications that could extend protection up to 2044.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.05%
Tags
-
Rhea-AI Summary
IMUX: Positive Interim Analysis from Phase 2 CALLIPER Trial Shows Improvements in Serum Neurofilament Light Chain for Vidofludimus Calcium, Consistent Throughout the Overall Progressive Multiple Sclerosis Population and All Subtypes
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.17%
Tags
Rhea-AI Summary
Immunic, Inc. (Nasdaq: IMUX) will release its Q3 financial results on November 14, 2023, before the opening of the U.S. financial markets. The webcast to discuss the results and provide a corporate update will be held at 8:00 am ET on the same day. Participants can register in advance on Immunic's website and will receive a confirmation email with the participation link or dial-in access.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.54%
Tags
-
Rhea-AI Summary
Biotech company Immunic, Inc. has received a Notice of Allowance from the USPTO for a patent application related to the treatment of Multiple Sclerosis with DHODH inhibitors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.88%
Tags
-
Rhea-AI Summary
Biotech company Immunic, Inc. will present data from its phase 1b clinical trial of IMU-856, a small molecule modulator for celiac disease, at the AOECS conference. They will also attend BIO-Europe for partnering activities.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.92%
Tags
Rhea-AI Summary
Immunic announces positive results from phase 2 trial of vidofludimus calcium in ulcerative colitis
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.65%
Tags
Immunic, Inc.
Nasdaq:IMUX
IMUX Rankings
IMUX Stock Data
111.70M
49.38M
7.72%
58.06%
3.37%
Pharmaceutical Preparation Manufacturing
Manufacturing
United States of America
NEW YORK
About IMUX
immunic, inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases, including relapsing-remitting multiple sclerosis, ulcerative colitis, crohn's disease, and psoriasis. its lead development program is imu-838, a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme dihydroorotate dehydrogenase, which is in phase 2 clinical development for treatment of ulcerative colitis and relapsing-remitting multiple sclerosis, as well as in phase 2 trial to treat crohn's disease. the company is also developing imu-935, an inverse agonist of rorgt; and imu-856 for the restoration of the intestinal barrier function in patients suffering from diseases, such as inflammatory bowel disease, irritable bowel syndrome with diarrhea, immune checkpoint inhibitor induced colitis, and other intestinal barrier function diseases. immu